Jazz Pharmaceuticals PLC (JAZZ)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $15.50B
Last updated: Nov 17, 2026 at 11:05 AM ET
Jazz Pharmaceuticals PLC (JAZZ) Competitors
The companies most similar to Jazz Pharmaceuticals are Ascendis Pharma AS (ASND), Halozyme Therapeutics (HALO) and Rhythm Pharmaceuticals (RYTM). Jazz Pharmaceuticals trades at 18.4x earnings, against a median of 18.5x for the 4 of these companies with a P/E. By market cap, Jazz Pharmaceuticals ranks 5th of the 13 companies on this page; Royalty Pharma Plc (RPRX) is the largest at $39.85B.
Peer Comparison
JAZZ's ROIC of 3.5% is above the peer median of -2.6%, and its revenue growth of 10.4% is below the median of 55.4%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Jazz Pharmaceuticals (JAZZ) | $15.50B | 18.4x | 3.3x | 4.4% | 3.5% | 10.4% | 0.00% |
| Ascendis Pharma AS (ASND) | $18.06B | N/A | 13.5x | 72.9% | 12.4% | 73.0% | 0.00% |
| Halozyme Therapeutics Inc (HALO) | $11.43B | 17.8x | 6.1x | 26.9% | 15.8% | 39.2% | 0.00% |
| Rhythm Pharmaceuticals Inc (RYTM) | $7.97B | N/A | 26.4x | -69.0% | -98.6% | 79.6% | 0.00% |
| Summit Therapeutics PLC (SMMT) | $11.32B | N/A | N/A | 0.0% | N/A | -100.0% | 0.00% |
| BridgeBio Pharma Inc (BBIO) | $15.25B | N/A | 16.0x | -59.8% | -33.0% | 192.6% | 0.00% |
| Praxis Precision Medicines Inc (PRAX) | $9.17B | N/A | N/A | 0.0% | N/A | 1349.0% | 0.00% |
| Madrigal Pharmaceuticals Inc (MDGL) | $9.93B | N/A | 8.7x | -10.9% | -12.7% | 50.1% | 0.00% |
| TG Therapeutics Inc (TGTX) | $9.75B | 87.2x | 11.1x | 11.8% | 11.0% | 60.7% | 0.00% |
| Spyre Therapeutics Inc. (SYRE) | $9.88B | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Exelixis Inc (EXEL) | $16.84B | 19.3x | 6.9x | 35.4% | N/A | 10.2% | 0.00% |
| Insmed Inc (INSM) | $26.58B | N/A | 17.7x | -39.9% | -44.2% | 268.4% | 0.00% |
| Royalty Pharma Plc (RPRX) | $39.85B | 12.9x | 11.7x | 25.7% | 7.6% | 13.3% | 1.37% |
| Peer median | $11.37B | 18.5x | 11.7x | 0.0% | -2.6% | 55.4% | 0.00% |
Similar Companies
These are the 12 companies most similar to Jazz Pharmaceuticals, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Ascendis Pharma AS (ASND) | Ascendis Pharma A / S, a biopharmaceutical company, develops therapies for unmet medical needs. The company is headquartered in Hellerup, Denmark. | ASND competitors |
| Halozyme Therapeutics Inc (HALO) | Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. | HALO competitors |
| Rhythm Pharmaceuticals Inc (RYTM) | Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment... | RYTM competitors |
| Summit Therapeutics PLC (SMMT) | Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and markets drugs to treat infectious diseases in the United States, Latin America... | SMMT competitors |
| BridgeBio Pharma Inc (BBIO) | BridgeBio Pharma, Inc. is dedicated to the discovery, development and supply of various drugs for genetic diseases. | BBIO competitors |
| Praxis Precision Medicines Inc (PRAX) | Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal... | PRAX competitors |
| Madrigal Pharmaceuticals Inc (MDGL) | Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates... | MDGL competitors |
| TG Therapeutics Inc (TGTX) | TG Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the acquisition, development... | TGTX competitors |
| Spyre Therapeutics Inc. (SYRE) | Spyre Therapeutics, Inc., a biotechnology company, focuses on advancing a pipeline of antibody therapeutics for the treatment of inflammatory bowel disease by... | SYRE competitors |
| Exelixis Inc (EXEL) | Exelixis, Inc., an oncology-focused biotechnology company, is focused on the discovery, development... | EXEL competitors |
| Insmed Inc (INSM) | Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. | INSM competitors |
| Royalty Pharma Plc (RPRX) | Royalty Pharma plc is a buyer of biopharmaceutical royalties and funder of innovations in the biopharmaceutical industry in the United States. | RPRX competitors |
Frequently Asked Questions About JAZZ
Who are Jazz Pharmaceuticals' main competitors?
The companies most similar to Jazz Pharmaceuticals include Ascendis Pharma AS (ASND), Halozyme Therapeutics (HALO), Rhythm Pharmaceuticals (RYTM), Summit Therapeutics (SMMT) and BridgeBio Pharma (BBIO), listed from the closest match.
Who is Jazz Pharmaceuticals' biggest competitor?
Royalty Pharma Plc (RPRX) is the largest of the similar companies at $39.85B; Ascendis Pharma AS (ASND) is the closest match by business profile, size, sector and industry.
How does JAZZ stock compare with its competitors?
JAZZ's P/E is 18.4x against a peer median of 18.5x; its P/S is 3.3x against a peer median of 11.7x; its net margin is 4.4% against a peer median of 0.0%.
Which of Jazz Pharmaceuticals' competitors pays a higher dividend?
Jazz Pharmaceuticals pays no dividend. Royalty Pharma Plc (RPRX) has a higher forward dividend yield; Royalty Pharma Plc (RPRX) has the highest at 1.37%.
Is Jazz Pharmaceuticals bigger than its competitors?
No. Jazz Pharmaceuticals is 5th by market cap among the 13 companies on this page; the largest is Royalty Pharma Plc (RPRX) at $39.85B.
JAZZ pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts